Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALLO allogene.com
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. These are off-the-shelf cell therapies designed to be readily available on demand, more reliably and at greater scale than patient-derived autologous CAR T.
Its pipeline includes:
- **Cema-cel (cemacabtagene ansegedleucel):** the lead candidate, in the pivotal Phase 2 ALPHA3 trial as MRD-guided first-line consolidation in large B-cell lymphoma, including at community oncology practices.
- **ALLO-329:** a dual CD19/CD70 AlloCAR T built with the proprietary Dagger technology, in the Phase 1 RESOLUTION trial for systemic sclerosis, myositis and lupus. It aims to reduce or eliminate chemotherapy-based lymphodepletion.
- **ALLO-316:** an anti-CD70 candidate in the Phase 1 TRAVERSE trial for renal cell carcinoma.
- **Preclinical candidates:** including a DLL3/CD70 dual CAR T for small cell lung cancer and other neuroendocrine tumors.
The oncology AlloCAR T products use Cellectis technologies. Allogene holds exclusive rights to cema-cel in the U.S., EU and UK through Servier, and global rights to the anti-CD70 program. ALLO-329 uses CRISPR gene editing. The company has no product revenue and has begun early commercial-readiness work for cema-cel, focused on payer coverage, reimbursement and treatment-site readiness. Updated
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Penny stocks are some of my favorite stocks to watch. When these young budding companies release news, their stock prices can make tremendous moves. Of course, if the news is positive, those…
With the earnings season winding down and windows for making insider purchases opening up, insiders have been scooping up shares of these six stocks.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Monday's top analyst upgrades and downgrades included Accenture, Analog Devices, Baxter International, Best Buy, Coinbase Global, Johnson Controls, Lam Research, Micron Technology and Qualcomm.
Thursday's top analyst upgrades and downgrades included AppLovin, Carvana, CrowdStrike, DocuSign, Fisker, Foot Locker, Intuitive Surgical, Rivian Automotive, Shopify, UnitedHealth, Workday and XPO Logistics.
Friday's additional top analyst upgrades and downgrades included Allogene Therapeutics, CSX, Norfolk Southern, Qualcomm, Toyota and Yelp.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 1.5 million shares of Allogene on December 14.
Friday's top analyst upgrades and downgrades included Caesars Entertainment, Charter Communications, Conagra Brands, Corning, Denny’s, General Electric, Home Depot, Plug Power, Sirius XM, 3M and Union Pacific.
Monday’s top analyst upgrades and downgrades included Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and more.
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease.
The Wall Street consensus 12-month price target for ALLO is $9.00.
